Pardes Biosciences, Inc. (PRDS) Research

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.

Market snapshot

Symbol
PRDS
Price
$2.18
Day change
+0.93%
Market cap
$135.2M
P/E ratio
-1.36x
52-week range
0.75-3.67
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • aTyr Pharma, Inc. (ATYR)
  • Decibel Therapeutics, Inc. (DBTX)
  • Graybug Vision, Inc. (GRAY)
  • HilleVax, Inc. (HLVX)
  • Kinnate Biopharma Inc. (KNTE)
  • NGM Biopharmaceuticals, Inc. (NGM)
  • Paratek Pharmaceuticals, Inc. (PRTK)
  • Selecta Biosciences, Inc. (SELB)

Recent insider activity

  • Tananbaum James B. — J-Other (1000 shares) on 2023-08-31
  • Tananbaum James B. — D-Return (37500 shares) on 2023-08-31
  • Tananbaum James B. — D-Return (16813146 shares) on 2023-08-31
  • Tananbaum James B. — D-Return (75000 shares) on 2023-08-31
  • Tananbaum James B. — D-Return (37500 shares) on 2023-08-31

Open Pardes Biosciences, Inc. (PRDS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.